Levoximed - Instructions For Use, Tablets 500 Mg, Price, Analogues

2024 Author: Rachel Wainwright | [email protected]. Last modified: 2024-01-31 05:02

Levoximed

Levoximed: instructions for use and reviews

1. 1. Release form and composition
2. 2. Pharmacological properties
3. 3. Indications for use
4. 4. Contraindications
5. 5. Method of application and dosage
6. 6. Side effects
7. 7. Overdose
8. 8. Special instructions
9. 9. Application during pregnancy and lactation
10. 10. Use in childhood
11. 11. In case of impaired renal function
12. 12. Use in the elderly
13. 13. Drug interactions
14. 14. Analogs
15. 15. Terms and conditions of storage
16. 16. Terms of dispensing from pharmacies
17. 17. Reviews
18. 18. Price in pharmacies

Latin name: Levoximed

ATX code: J01MA12

Active ingredient: Levofloxacin (Levofloxacin)

Producer: Berko Ilach ve Kimya Sanayi A. Sh. (Berko İlaç ve Kimya Sanayi A. Ş.) (Turkey); Mefar Ilach Sanayi A. Sh. (Mefar İlaç Sanayii A. Ş.) (Turkey)

Description and photo updated: 2019-29-07

Prices in pharmacies: from 456 rubles.

Buy

Levoximed is a broad-spectrum antimicrobial drug for oral and parenteral use; refers to fluoroquinolones.

Release form and composition

The drug is available in the following dosage forms:

• film-coated tablets: biconvex, oblong, yellow, on one side with engravings "W" and "M", separated by a line, on the other - engraved "L250" (for tablets with a dosage of 250 mg) or "L500" (for tablets with a dosage of 500 mg) (7 pcs. in blisters, in a cardboard box 1 blister and instructions for medical use of Levoximed);
• solution for infusion: a clear greenish-yellow liquid (100 ml each in colorless glass vials closed with a rubber stopper and an aluminum Flip-off cap; in a cardboard box one bottle and instructions for use of Levoximed).

Composition for 1 film-coated tablet:

• active substance: levofloxacin (in the form of levofloxacin hemihydrate) - 250 mg or 500 mg;
• auxiliary components of the tablet core: crospovidone, microcrystalline cellulose, sodium stearyl fumarate, hydroxypropyl methylcellulose;
• film casing: Opadry yellow II (titanium dioxide, talc, polyvinyl alcohol, quinoline yellow aluminum varnish, macrogol, Ponso 4R aluminum varnish).

Composition for 1 ml of solution for infusion:

• active substance: levofloxacin (in the form of levofloxacin hemihydrate) - 5 mg;
• auxiliary components: concentrated hydrochloric acid, sodium chloride, water for injection, sodium hydroxide solution 10%.

The theoretical osmolarity of the infusion solution is 280–320 mOsm / kg.

Pharmacological properties

Pharmacodynamics

The active ingredient of Levoximed, levofloxacin, is an optically active levorotatory isomer of ofloxacin - L-ofloxacin. It belongs to the group of fluoroquinolones and has antimicrobial effect. The drug blocks the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV, disrupts the process of supercoiling and stitching of breaks in DNA strands, inhibits DNA synthesis, and also causes serious morphological changes in membranes, cell walls and the cytoplasm of microbes.

In vivo and in vitro conditions, Levoximed is active against most strains of bacteria and other microorganisms.

The following microorganisms are sensitive to levofloxacin (the minimum inhibitory concentration is 2 mg / l or less, and the zone of inhibition is 17 mm or more):

• aerobic gram-negative bacteria: Acinetobacter spp. (including Acinetobacter baumannii), Enterobacter spp. (including Enterobacter aerogenes and Enterobacter cloacae), Aggregatibacter actinomycetemcomitans, Haemophilus influenzae ampi-S / R (ampicillin susceptible strains and ampicillin resistant strains) and Haemophilus parainfluenzae, Haemophilus spp. (including Klebsiella pneumoniae and Klebsiella oxytoca), Morganella morganii, Eikenella corrodens, Moraxella catarrhalis f + / f- (beta-lactamase-producing strains / non-beta-lactamase-producing strains), Gardnerella vaginal pylorilla, Helicobacter. (including Pasteurella dagmatis, Pasteurella canis and Pasteurella multocida), Pseudomonas spp. (including Pseudomonas aeruginosa), Escherichia coli, Salmonella spp., Neisseria meningitidis,Neisseria gonorrhoeae non.png" />
• aerobic gram-positive bacteria: Enterococcus spp. (including Enterococcus faecalis), Staphylococcus spp. CNS (coagulase negative strains), Staphylococcus coagulase-negative methi-S (I) (coagulase negative methicillin sensitive strains / moderate methicillin sensitive strains), Staphylococcus epidermidis methi-S (methicillin) -sensitive strains susceptible strains), Viridans streptococci peni-S / R (penicillin susceptible strains / penicillin resistant strains), Bacillus anthracis, Streptococcus agalactiae, Streptococcus pyogenes, Streptococcus pneumoniae peni-I / S / R (moderately susceptible to penicillin penicillin strains / penicillin resistant strains), Listeria monocytogenes, Corynebacterium jeikeium and Corynebacterium diphtheriae,Streptococci groups C and G;
• anaerobic bacteria: Clostridium perfringens, Propionibacterium spp., Bacteroides fragilis, Veilonella spp., Bifidobacterium spp., Fusobacterium spp., Peptostreptococcus spp.;
• other microorganisms: Mycobacterium spp. (including Mycobacterium tuberculosis and Mycobacterium leprae), Bartonella spp., Rickettsia spp., Chlamydia psittaci, Chlamydia pneumoniae, Chlamydia trachomatis, Ureaplasma urealyticum, Legionella spp. (including Legionella pneumophila), Mycoplasma pneumoniae, Mycoplasma hominis.

The following bacteria are moderately sensitive to Levoximed (the minimum inhibitory concentration is 4 mg / l, and the zone of inhibition is 16-14 mm):

• aerobic gram-negative bacteria: Campylobacter jejuni / coli;
• aerobic gram-positive bacteria: Staphylococcus haemolyticus methi-R (methicillin-resistant strains), Staphylococcus epidermidis methi-R (methicillin-resistant strains), Corynebacterium xerosis, Corynebacterium urealyticus fae, Enterococcium;
• anaerobic bacteria: Porphyromonas spp., Prevotella.

The following microorganisms are resistant to levofloxacin (with a minimum inhibitory concentration of 8 mg / l or more and an inhibition zone of 13 mm or less):

• aerobic gram-negative bacteria: Alcaligenes xylosoxidans;
• aerobic gram-positive bacteria: Staphylococcus coagulase-negative methi-R (coagulase-negative methicillin-resistant strains), Staphylococcus aureus methi-R (methicillin-resistant strains);
• anaerobic bacteria: Bacteroides thetaiotaomicron;
• other bacteria: Mycobacterium avium.

The sensitivity of microorganisms to Levoximed can be reduced as a result of the gradual mutation of genes that encode both topoisomerases, as well as due to resistance mechanisms such as efflux (active elimination of antimicrobial substances from microbial cells) and the mechanism of action on the penetration barriers of microbial cells (this path of development of resistance is typical for Pseudomonas aeruginosa).

Due to the peculiarities of the mechanism of action between Levoximed and other antimicrobial drugs, cross-resistance usually does not occur.

Clinical studies have shown the effectiveness of levofloxacin against the following microorganisms:

• aerobic gram-negative bacteria: Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Citrobacter freundii, Serratia marcescens, Enterobacter cloacae, Moraxella (Branhamella) catarrhalis, Haemophilus influenzae and Haemophilus parainfluenzae, Morganella;
• aerobic gram-positive bacteria: Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, Streptococcus pneumoniae;
• other bacteria: Legionella pneumophila, Chlamydia pneumoniae, Mycoplasma pneumoniae.

Pharmacokinetics

After taking Levoximed inside, Levofloxacin is absorbed quickly and almost completely. Food intake has practically no effect on the absorption of the active substance. Bioavailability after oral administration is 99-100%. The maximum plasma concentration after taking 500 mg of the drug orally or intravenously (intravenous) injection for 60 minutes is achieved after 1-2 hours and is 5.2-6.2 μg / ml.

Pharmacokinetics of Levoximed is linear in the dose range of 50–1000 mg. The equilibrium state is achieved on average within 48 hours (when taking or administering 500 mg of the drug once or twice a day).

About 30-40% of levofloxacin binds to whey proteins. The volume of distribution after a single and repeated administration of Levoximed at a dose of 500 mg is 100 liters. This indicates a good penetration of the active substance into tissues and organs. Levofloxacin penetrates into lung tissue and alveolar fluid, bronchial mucosa, alveolar macrophages and bronchial epithelial lining fluid, into bone tissue, cerebrospinal fluid, prostate tissue and urine.

No more than 5% of the active substance is metabolized. The resulting metabolites (levofloxacin N-oxide and dimethyl levofloxacin) are excreted by the kidneys. Levofloxacin itself is stereochemically stable and not subject to chirality.

The half-life of the drug is 6-8 hours. More than 85% of the dose taken or administered intravenously is eliminated by the kidneys. After a single dose (injection) of 500 mg of levofloxacin, the total clearance is 175 ± 29.2 ml / min.

With oral and intravenous administration of Levoximed, the pharmacokinetics of the drug do not differ significantly, that is, taking levofloxacin orally and its intravenous administration are interchangeable.

Pharmacokinetic parameters of the drug in women and men do not differ. There are also no differences in the pharmacokinetics of levofloxacin in elderly and young patients (except for cases when the patient has renal dysfunction).

In patients with renal insufficiency, a change in the pharmacokinetics of the drug is observed (renal clearance decreases, and the half-life increases).

Indications for use

Levoximed is used to treat infectious and inflammatory diseases caused by microorganisms that are sensitive to levofloxacin, namely:

• acute sinusitis;
• chronic bronchitis in the acute stage;
• community-acquired pneumonia;
• infections of soft tissues and skin;
• drug-resistant forms of tuberculosis (as part of a combination treatment);
• complicated and uncomplicated urinary tract infections (including pyelonephritis);
• treatment and prevention of anthrax (when the infection is transmitted by airborne droplets);
• chronic bacterial prostatitis.

When using Levoximed, it is necessary to take into account national recommendations for the use of antibacterial agents, as well as the sensitivity of bacteria to levofloxacin in a particular country.

Contraindications

Absolute:

• tendon lesions while taking fluoroquinolones (including a history);
• pseudoparalytic myasthenia gravis;
• epilepsy;
• period of pregnancy and lactation;
• children up to age 18;
• increased individual sensitivity to levofloxacin, auxiliary components of the drug and / or other antimicrobial agents from the quinolone group.

Relative (Levoximed is used with caution):

• impaired renal function (it is necessary to monitor renal function and adjust the dosage regimen);
• predisposition to the development of seizures (the presence of previous lesions of the central nervous system; concomitant use of drugs that reduce the threshold of seizure readiness of the brain, for example, theophylline or fenbufen);
• the presence of risk factors for prolongation of the QT interval (uncorrected electrolyte disturbances; heart disease, for example, bradycardia, myocardial infarction and heart failure; congenital prolongation of the QT interval syndrome; advanced age; female patients; concomitant use of drugs that can prolong the QT interval, such as antipsychotics, macrolides, tricyclic antidepressants, etc.);
• history of psychosis or mental illness;
• manifested or latent deficiency of the enzyme glucose-6-phosphate dehydrogenase (due to an increased risk of hemolytic reactions);
• simultaneous administration of oral hypoglycemic agents or insulin in patients with diabetes mellitus (due to the risk of hypoglycemia);
• severe adverse reactions to other drugs from the fluoroquinolone group (for example, severe neurological responses).

Levoximed, instructions for use: method and dosage

Film-coated tablets

In the form of film-coated tablets, Levoximed 500 mg or 250 mg is intended for oral administration 1-2 times a day. The tablet should not be chewed. It should be swallowed whole with a sufficient amount of water or other liquid (100-200 ml). If necessary, the tablet can be broken in half at the dividing risk.

Levoximed tablets can be taken both before meals and during or after meals, since the absorption of the drug does not depend on the diet. Levofloxacin should not be taken simultaneously with medicines containing zinc, iron, aluminum and / or magnesium, as well as sucralfate. The interval between taking Levoximed and the listed drugs should be at least 2 hours.

When a patient is transferred from i.v. administration of levofloxacin to the oral form of the drug, the daily dose remains unchanged, since the bioavailability of levoximed in tablets is almost 100% (as with i.v. infusion).

If you skip taking the drug, you should take the usual dose as soon as possible and continue taking levofloxacin according to the prescribed dosage regimen.

The dose of Levoximed is set based on the severity and nature of the infection. In addition, the sensitivity of the suspected pathogen should be considered. The course of treatment may vary depending on the course of the disease.

Recommended doses of Levoximed and duration of therapy with normal renal function (creatinine clearance more than 50 ml / min):

• exacerbation of chronic bronchitis, pyelonephritis: 500 mg once a day for 7-10 days;
• acute sinusitis: 500 mg once a day for 10-14 days;
• community-acquired pneumonia, soft tissue and skin infections: 500 mg once or twice a day for 7-14 days;
• drug-resistant forms of tuberculosis: 500 mg once or twice a day for up to 3 months;
• complicated urinary tract infections: 500 mg once a day for 7-14 days;
• uncomplicated urinary tract infections: 250 mg once a day for 3 days;
• treatment and prevention of anthrax (with airborne infection): 500 mg once a day for up to 8 weeks;
• chronic bacterial prostatitis: 500 mg once a day for 28 days.

In case of impaired renal function, the dose of Levoximed and the frequency of application of the drug are adjusted depending on the CC (creatinine clearance):

• CC 50–20 ml / min: with a recommended dose of 250 mg once a day, the initial dose is 250 mg, and then 125 mg once a day; at a recommended dose of 500 mg once a day, the initial dose is 500 mg, and then 250 mg once a day; at the recommended dose of Levoximed 500 mg twice a day, the initial dose is 500 mg, and then 250 mg twice a day;
• CC 19-10 ml / min: with a recommended dose of 250 mg once a day, the initial dose is 250 mg, and then 125 mg once every 48 hours; at a recommended dose of 500 mg once a day, the initial dose is 500 mg, and then 125 mg once a day; at a recommended dose of 500 mg twice a day, the initial dose is 500 mg, and then 125 mg twice a day;
• CC less than 10 ml / min (including patients on hemodialysis or continuous outpatient peritoneal dialysis): with a recommended dose of 250 mg once a day, the initial dose is 250 mg, and then 125 mg once every 48 hours; at a recommended dose of 500 mg once a day, the initial dose is 500 mg, and then 125 mg once a day; at a recommended dose of 500 mg twice a day, the initial dose is 500 mg, and then 125 mg once a day.

In patients with impaired liver function, Levoximed is used in usual doses, since only a small amount of Levofloxacin undergoes hepatic metabolism.

In old age, the dose of the drug is not adjusted (except for cases of impaired renal function and a decrease in CC less than 50 ml / min).

Solution for infusion

Levoximed in the form of a solution for infusion is injected into / in slowly drip. The duration of the course of treatment depends on the course of the disease and can vary significantly depending on the severity of the infection. Like other antibiotics, levofloxacin should be used for at least another 2-3 days after the temperature has returned to normal and the pathogen has been reliably destroyed. Treatment cannot be interrupted or terminated early without a doctor's instructions.

The duration of one infusion (100 ml vial with the drug, which corresponds to 500 mg of levofloxacin) is at least 60 minutes. If the patient is injected with half a bottle (50 ml of solution, which corresponds to 250 mg of levofloxacin), then the duration of administration should be at least 30 minutes.

Solution for infusion Levoximed is compatible with 5% dextrose solution, 0.9% sodium chloride solution, combined solutions for parenteral nutrition (carbohydrates, electrolytes, amino acids) and 2.5% Ringer's solution with dextrose.

Levoximed should not be mixed with solutions that have an alkaline reaction (sodium bicarbonate solution, etc.), as well as heparin.

The recommended doses and duration of treatment with Levoximed in the form of a solution for infusion are similar to the doses and duration of therapy when using the drug in the form of film-coated tablets. The data on the correction of the dosage regimen of levofloxacin in patients with impaired renal function are also valid.

If the patient's condition improves, it is possible to transfer it from parenteral to oral form of Levoximed in the same doses.

Side effects

As a result of clinical studies and in the process of post-marketing use of Levoximed, side effects from the following systems and organs were identified:

• digestive system: often - nausea, vomiting, loose stools; infrequently - dyspeptic disorders, abdominal pain, constipation, flatulence; frequency unknown - hemorrhagic diarrhea, enterocolitis, pancreatitis, pseudomembranous colitis;
• hepatobiliary system: often - increased activity of liver enzymes, alkaline phosphatase and gamma glutamyl transferase; infrequently - an increase in the level of bilirubin in the blood; frequency unknown - jaundice, hepatitis, severe liver failure;
• metabolism and nutrition: infrequently - anorexia; rarely (mainly in patients with diabetes mellitus) - hypoglycemia (manifested by nervousness, ravenous appetite, tremors and perspiration); frequency unknown - hypoglycemic coma, hyperglycemia;
• respiratory system: infrequently - shortness of breath; frequency unknown - allergic pneumonitis, bronchospasm;
• cardiovascular system: rarely - lowering blood pressure, palpitations, sinus tachycardia; frequency unknown - ventricular tachycardia (including the "pirouette" type), ventricular arrhythmias, lengthening of the QT interval;
• nervous system: often - dizziness, headache; infrequently - tremors, drowsiness, taste perversion; rarely - convulsions, paresthesia; frequency unknown - dyskinesia, loss of taste, peripheral sensory and sensory-motor neuropathy, odor sensation disorder (up to loss of smell), extrapyramidal disorders, benign intracranial hypertension, syncope;
• mental disorders: often - insomnia; infrequently - anxiety, anxiety, confusion; rarely - depression, agitation, nightmares, paranoia, sleep disturbances, hallucinations; frequency unknown - suicidal thoughts and attempts;
• sense organs: infrequently - vertigo; rarely - ringing in the ears; very rarely - blurring of the visible image; frequency unknown - hearing loss or loss, transient vision loss;
• lymphatic system and blood: infrequently - an increase in the number of eosinophils, a decrease in the number of leukocytes; rarely - a decrease in the number of platelets and neutrophils; frequency unknown - hemolytic anemia, a sharp decrease or absence of granulocytes, a decrease in the number of all blood cells;
• skin and subcutaneous fat: infrequently - increased sweating, pruritus, rash, urticaria; frequency unknown - photosensitization, stomatitis, exudative erythema multiforme, leukocytoclastic vasculitis, Stevens-Johnson syndrome, toxic epidermal necrolysis;
• urinary system: infrequently - an increase in the concentration of serum creatinine; rarely - acute renal failure;
• musculoskeletal system: infrequently - myalgia, arthralgia; rarely - muscle weakness (especially dangerous for patients with myasthenia gravis), tendonitis and other tendon lesions; frequency unknown - rupture of ligaments, muscles or tendons, arthritis, rhabdomyolysis;
• parasitic and infectious diseases: infrequently - the development of resistance of pathogenic microbes, fungal infections;
• immune system: rarely - Quincke's edema; frequency is unknown - anaphylactoid and anaphylactic shock (possible even after taking the initial dose);
• general reactions: infrequently - asthenia; rarely - an increase in body temperature; frequency unknown - pain in the chest, back, limbs and other parts of the body;
• adverse reactions characteristic of all fluoroquinolones: attacks of porphyria (in patients with porphyria), uveitis.

Overdose

Data from toxicological studies of levofloxacin, conducted on animals, suggest that the main symptoms of an overdose of Levoximed relate to the digestive system (nausea, erosion of the mucous membranes of the gastrointestinal tract) and the central nervous system (tremor, dizziness, disturbance and confusion of consciousness, hallucinations, convulsions) … According to the results of the studies, it was revealed that in patients who took the drug in doses exceeding the recommended ones, there was an increase in the QT interval on the ECG (electrocardiogram). In case of an overdose, the patient should be under close supervision, including ECG monitoring.

Symptomatic treatment is carried out. The patient should be gastric lavage and antacids should be prescribed, which protect the gastric mucosa from damage. There are no specific antidotes. Hemodialysis is ineffective.

special instructions

For nosocomial infections with Pseudomonas aeruginosa (Pseudomonas aeruginosa), combination therapy may be required.

In case of ineffectiveness of the treatment, as well as in patients with severe infections, it is necessary to establish a microbiological diagnosis (isolate the pathogen and determine its sensitivity to the drug).

Levoximed is not recommended for the treatment of suspected or established infections caused by methicillin-resistant strains of Staphylococcus aureus, as it is highly likely that it will be resistant to levofloxacin therapy.

Diarrhea that develops during the use of Levoximed or after the end of treatment, especially persistent (including blood), may be a sign of pseudomembranous colitis, which is caused by the bacterium Clostridium difficile. If this disease is suspected, therapy should be discontinued and the patient should be prescribed appropriate antibacterial drugs (metronidazole, vancomycin or teicoplanin orally). You can not use drugs that slow down the intestinal motility.

Elderly patients are more susceptible to developing tendonitis than young people. In some cases, this side effect develops within 48 hours after starting therapy. The likelihood of tendonitis increases in patients who take glucocorticosteroids simultaneously with levofloxacin.

With the development of severe allergic reactions, especially from the mucous membranes and skin, treatment with the drug should be discontinued and urgently consult a doctor.

In patients with impaired renal function during therapy with Levoximed, it is necessary to monitor renal function.

In order to prevent photosensitization during the period of treatment with the drug, as well as within two days after the end of therapy, the patient is not recommended to visit the solarium and be exposed to intense solar radiation.

Treatment with levofloxacin, especially long-term, can lead to active reproduction of insensitive fungi and bacteria, and cause a change in normal microflora, which ultimately can lead to the development of superinfection. During therapy, it is necessary to re-evaluate the patient's condition, and in the event of a superinfection, take appropriate measures.

In patients with diabetes mellitus during treatment with Levoximed, blood sugar levels should be measured regularly (to avoid the development of hypo- or hyperglycemia).

When symptoms of neuropathy appear, as well as psychotic reactions, it is necessary to discontinue therapy with levofloxacin, which minimizes the potential risk of irreversible changes.

In case of visual impairment, the patient is advised to urgently consult an ophthalmologist.

Levofloxacin can change the results of laboratory tests, for example, when determining opiates in urine, false-positive results may appear, which must be confirmed by more accurate and specific methods.

Levoximed can inhibit the growth of Mycobacterium tuberculosis and make it difficult to make a correct diagnosis later.

With intravenous infusion, it is necessary to strictly adhere to the recommended rate and duration of solution administration. During infusion, a transient decrease in blood pressure and an increase in heart rate are possible, and in rare cases, vascular collapse. With a pronounced decrease in blood pressure, the administration of Levoximed should be stopped immediately.

Influence on the ability to drive vehicles and complex mechanisms

Some side effects of levofloxacin (for example, vertigo, visual impairment, drowsiness) can affect concentration and psychomotor reaction speed, which can pose a certain risk in situations where these qualities are especially important (while driving, when working with other cars, etc. mechanisms, etc.).

Application during pregnancy and lactation

Levoximed is contraindicated during pregnancy and breastfeeding, as there is a risk of damage to the cartilaginous growth points in the fetus and child.

Pediatric use

Levoximed should not be used in children and adolescents under 18 years of age (due to the high risk of damage to cartilaginous growth points).

With impaired renal function

In patients with impaired renal function, it is necessary to adjust the dose of levofloxacin depending on the CC value.

Use in the elderly

In old age, Levoximed is used with caution, since in patients over 65 years of age there is a high probability of concomitant deterioration of renal function.

Drug interactions

Levofloxacin and preparations containing aluminum, zinc, iron and magnesium, as well as sucralfate are not recommended to be taken simultaneously. The interval between taking Levoximed tablets and the listed funds should be at least 2 hours.

Calcium salts have practically no effect on the systemic absorption of the drug when administered orally.

With the combined use of levofloxacin with fenbufen, theophylline, nonsteroidal anti-inflammatory drugs and other drugs that lower the seizure threshold, a significant decrease in the readiness of the brain for a seizure response is possible.

Levofloxacin is carefully combined with indirect anticoagulants (regular monitoring of blood clotting parameters is required).

In patients with renal insufficiency, drugs that disrupt renal tubular secretion (cimetidine and probenecid) should be used with caution simultaneously with levofloxacin, since these drugs slow down its excretion.

Levoximed slightly increases the half-life of cyclosporine.

Glucocorticosteroids increase the likelihood of tendon rupture when used together with levofloxacin.

All fluoroquinolones are used with caution together with drugs that prolong the QT interval (tricyclic antidepressants, antipsychotics, class IA and III antiarrhythmics, macrolides, etc.).

There were no pharmacokinetically significant (for levofloxacin) interactions with ranitidine, digoxin, warfarin and glibenclamide.

Analogs

Levoksimed analogues are Glevo, Ashlev, Ivacin, Levostar, Levolet R, Lebel, Levotek, Levofloxabol, Levoflox-Routek, Levoflox, Levofloxacin, Levofloxacin-Teva, Levofloxacin-Nova, Levofloxacin-LEKSVMTA-Aliofloxafacin, LEXVMTA, Levofloxatefl Leflobact, Leobag, Lufy, Lefsan, Lefokcin, OD-Levox, Maklevo, Tanflomed, Tavanik, Roflox-Scan, Remedia, Haileflox, Eleflox, Ekolevid, Fleksid, Floracid.

Terms and conditions of storage

Keep out of the reach of children. Store at a temperature not exceeding 25 ° C.

The shelf life of the drug is 3 years.

Terms of dispensing from pharmacies

Dispensed by prescription.

Reviews about Levoximed

There are not many reviews about Levoximed. Basically, patients respond positively to the drug. Levofloxacin is a broad-spectrum antimicrobial agent and is effective against various bacterial infections. It is convenient to take the tablets, since once a day is usually sufficient.

As a disadvantage, it is most often indicated that tablets and solution for infusion are not always present in the range of pharmacies.

Price for Levoximed in pharmacies

The price of Levoximed in the form of 500 mg film-coated tablets (7 pcs per pack) is 430–540 rubles. The cost of a solution for infusion in 100 ml vials is about 380-400 rubles.

Levoximed: prices in online pharmacies

Drug name Price Pharmacy

Levoximed 500 mg film-coated tablets 7 pcs. 456 r Buy

Maria Kulkes Medical journalist About the author

Education: First Moscow State Medical University named after I. M. Sechenov, specialty "General Medicine".

Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!